GlassScriptPhysician profile
James M Hart
NPI 1093196420
$2,230.64
in general payments reported to CMS, 2019-2025
28 companies · $716 in 2025
The $716 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $43.40 · 2022: $146 · 2023: $343 · 2024: $763 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $416.39 | 2022-2025 | |
| Pfizer INC. | $384.39 | 2019-2025 | |
| Genzyme Corporation | $123.81 | 2024 | |
| Asahi Intecc USA, INC. | $118.08 | 2024 | Peripheral Vascular |
| Astrazeneca Pharmaceuticals LP | $115.48 | 2019-2025 | Airsupra, Breztri |
| E.R. Squibb & Sons, L.L.C. | $110.25 | 2019-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $82.70 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $81.72 | 2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $79.77 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $74.51 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $61.46 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $57.42 | 2022-2023 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.24 | 2024-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $50.82 | 2024-2025 | Gemtesa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.60 | 2019-2023 | Lifevest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.77 | 2019-2023 | Xifaxan |
| Daxor Corporation | $41.16 | 2023 | Bva-100 |
| Otsuka America Pharmaceutical, INC. | $36.66 | 2024 | Rexulti |
| Dynavax Technologies Corporation | $34.59 | 2025 | Heplisav-B |
| Mallinckrodt Hospital Products INC. | $33.23 | 2022 | |
| Amgen INC. | $31.32 | 2024 | Repatha, Otezla |
| Astellas Pharma US INC | $27.80 | 2024-2025 | Veozah |
| Abbott Laboratories | $26.65 | 2024-2025 | Freestyle Libre 3 |
| Verona Pharma, INC. | $24.37 | 2025 | Ohtuvayre |
| Silk Road Medical, INC. | $20.13 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Xeris Pharmaceuticals, INC. | $16.30 | 2025 | Gvoke Hypopen |
| Baxter Healthcare | $16.22 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Melinta Therapeutics, LLC | $15.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.